- UCLA Jonsson Comprehensive Cancer Center member Dr. Owen Witte inducted into American Association for Cancer Research (AACR) Academy
- Witte’s research key to the development of the targeted cancer drugs Gleevec® and Imbruvica™
- AACR Academy fellows inducted by peer review
Scientist Dr. Owen Witte, UCLA Jonsson Comprehensive Cancer Center member and director of UCLA’s Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is a 2014 inductee into the American Association for Cancer Research (AACR) Academy.
Witte’s research laid the foundation for the development of the drug Imatinib (Gleevec®), the first targeted therapy for chronic myeloid leukemia.
“Our 2014 class of fellows includes a number of the most prestigious laboratory researchers and physician-scientists who have contributed enormously to the cancer field,” said Dr. Margaret Forti, chief executive officer of the AACR.
The Academy was created to recognize and honor distinguished scientists whose important research has significantly advanced the fight against cancer. The fellows of the Academy are selected by a rigorous peer-review process that evaluates them based on their scientific achievements in cancer research.
“I am honored to be recognized by the AACR with induction into the Academy,” Witte said. “The fact that fellows of the AACR Academy are selected by their peers based on their research achievements gives inclusion a much richer meaning than one might feel for an award based on one discovery. This honor acknowledges more than my career, it highlights the achievements of the many people who have worked and trained in my laboratory and all my colleagues over the years as well.”
Witte’s work also defined Bruton's tyrosine kinase, which has become a target therapy of several types of leukemia and lymphoma with drugs like ibrutinib. His research has focused on the interrelated problems of how cell growth is regulated, how cells differentiate, and understanding the function of cancer-causing genes in human leukemia and epithelial cancers (cancers of the lining of glands or organs such as the prostate or ovaries).
Witte is an active scientist currently working on defining the stem cells for epithelial cancers of the prostate and other organs to help define new and more effective therapies.
Witte graduated from Cornell University and earned his medical degree at Stanford. He completed his postdoctoral research at the Massachusetts Institute of Technology and later joined the UCLA faculty where he is a distinguished professor of microbiology, immunology and molecular genetics and a Howard Hughes Medical Institute Investigator. He currently holds the UCLA President’s Chair in Developmental Immunology.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.